New Developments in Follicular Lymphoma: Treatment Guidance and Clinical Resources

Gain insights for the multidisciplinary team on leveraging current and emerging therapies for optimal care of patients with follicular lymphoma across multiple settings with expert-authored commentaries, a text module, and downloadable PowerPoint slides and clinical resource PDF. Then, learn how the experts would treat your patients in the frontline and relapsed/refractory settings with an updated decision support tool.
John M. Burke, MD

ClinicalThought

How will you incorporate tazemetostat, an EZH2 inhibitor, into your clinical practice for patients with relapsed/refractory follicular lymphoma? Here are my thoughts.

John M. Burke, MD Released: August 4, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Bayer HealthCare Pharmaceuticals Inc.
Celgene Corporation
Epizyme Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue